Rating Change
RBC Capital analysts reiterated a Outperform rating on Ligand Pharmaceuticals Incorporated (OTC:LGNYZ) on July 15, 2026.
reiterateOTC:LGNYZ
RBC Capital Reiterates Outperform Rating on Ligand Pharmaceuticals Incorporated (LGNYZ)
Rating Change RBC Capital analysts reiterated a Outperform rating on Ligand Pharmaceuticals Incorporated (OTC:LGNYZ) on July 15, 2026. Market Context Ligand Pharmaceuticals…
Market Context
Ligand Pharmaceuticals Incorporated operates in the Healthcare sector. The stock currently trades at $0.04 with a market capitalization of $885.7K.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ligand Pharmaceuticals Incorporated.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ligand Pharmaceuticals Incorporated
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 15, 2026 | RBC Capital | Outperform | N/A |
| Jul 09, 2026 | B of A Securities | Buy | N/A |
| Jul 08, 2026 | Stifel | Buy | N/A |
| May 08, 2026 | RBC Capital | Outperform | N/A |
| Apr 30, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LGNYZ Stock Page
Frequently Asked Questions
What does a Outperform rating mean for LGNYZ?
A Outperform rating from RBC Capital reflects the analyst's outlook on Ligand Pharmaceuticals Incorporated (OTC:LGNYZ). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LGNYZ forecast page.